Every 8-K that Immunovant, Inc. (IMVT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IMVT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMVT filings page.
Immunovant, Inc. (IMVT) reported the results of its 2026 Annual Meeting of Stockholders held on September 2, 2026, with approximately 96% of common and Series A preferred shares entitled to vote represented in person or by proxy. Stockholders elected Jacob Bauer, Douglas Hughes and Robert Susman as directors until the 2027 annual meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending March 31, 2027, and approved, on a non-binding advisory basis, the compensation of Immunovant’s named executive officers as disclosed in the proxy statement.
Immunovant, Inc. reported corporate updates and financial results for its fiscal first quarter ended June 30, 2026, centered on the development of IMVT-1402 across six autoimmune indications, including Graves’ disease, myasthenia gravis, CIDP, difficult-to-treat rheumatoid arthritis, Sjögren’s disease and cutaneous lupus erythematosus.
As of June 30, 2026, cash and cash equivalents were $797.8 million, which the company states provides runway to the potential commercial launch of IMVT-1402 in Graves’ disease based on its current operating plan. For the quarter, R&D expenses were $142.6 million, up from $101.2 million a year earlier, mainly from IMVT-1402 clinical and manufacturing activities, while G&A expenses declined to $17.7 million from $26.0 million. Net loss was $153.2 million, or $0.75 per share, versus $120.6 million, or $0.71 per share, in the prior-year quarter. Non-GAAP measures exclude $13.8 million of non-cash stock-based compensation. The company highlighted upcoming IMVT-1402 milestones, including D2T RA and CLE data in the second half of 2026, GD and MG topline data in 2027, and CIDP and Sjögren’s data in 2028.
Immunovant, Inc. reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2026. Lead asset IMVT-1402 showed encouraging preliminary results in difficult-to-treat rheumatoid arthritis, with Week 16 ACR20, ACR50 and ACR70 response rates of 72.7%, 54.5% and 35.8% in the open-label period. A proof-of-concept trial in cutaneous lupus erythematosus is fully enrolled, and potentially registrational studies in Graves’ disease, myasthenia gravis, CIDP and Sjögren’s disease remain on track, with multiple topline readouts expected in 2026–2027. The company discontinued batoclimab after two Phase 3 thyroid eye disease trials did not meet their primary endpoint and is redirecting resources to IMVT-1402.
For the quarter, research and development expenses were $142.3 million and net loss was $147.9 million, or $0.73 per share. For the full fiscal year, research and development expenses were $456.7 million and net loss was $505.6 million, or $2.77 per share. Cash and cash equivalents totaled $902.1 million as of March 31, 2026, which management states provide runway through the potential commercial launch of IMVT-1402 in Graves’ disease.
Immunovant, Inc. reported a fiscal third-quarter 2025 net loss of $110.6 million, or $0.61 per share, driven mainly by research and development spending as it advances its autoimmune pipeline.
For the quarter ended December 31, 2025, R&D expenses were $98.9 million and general and administrative expenses were $15.4 million, with non-GAAP R&D and G&A at $91.1 million and $10.6 million, respectively. Nine-month net loss totaled $357.8 million, or $2.04 per share, with non-GAAP net loss of $312.9 million.
Cash and cash equivalents reached $994.5 million as of December 31, 2025, supported by an underwritten financing that generated approximately $550 million in gross proceeds, which the company believes extends its cash runway to the potential launch of IMVT-1402 in Graves’ disease. Key programs include a fully enrolled potentially registrational trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis, with topline data expected in the second half of 2026, additional potentially registrational IMVT-1402 trials across several autoimmune indications, and Phase 3 batoclimab data in thyroid eye disease expected in the first half of 2026.
Immunovant, Inc. reported that Michael Geffner, M.D., M.B.A., ceased serving as its Chief Medical Officer effective November 21, 2025, as part of a restructuring of the company’s R&D leadership under Chief Executive Officer Eric Venker, M.D., PharmD. The company and Dr. Geffner entered into a Separation Agreement and General Release that provides severance benefits consistent with his existing employment agreement and includes a standard release of claims in favor of the company.
To support continuity, Dr. Geffner will provide consulting services through April 30, 2026. During this consulting period, his outstanding equity awards will continue to vest under their current terms, and any unvested awards scheduled to vest during the consulting period will fully vest if a change in control occurs in that timeframe. Vested stock options may be exercised until the earlier of nine months after his consulting ends or their original expiration dates.
Immunovant, Inc. furnished an 8-K announcing a press release with financial results for its fiscal second quarter and six months ended September 30, 2025. The press release is included as Exhibit 99.1.
The company states the information under Item 2.02, including Exhibit 99.1, is furnished, not deemed “filed” under the Exchange Act, and will not be incorporated by reference in other SEC filings. The report was signed by Chief Financial Officer Tiago Girao.
Immunovant, Inc. reported that it issued a press release on September 3, 2025 providing an update on its Graves’ Disease development program. The press release is included as an exhibit and is incorporated by reference.
The company also posted an investor presentation on its website covering an update on its Graves’ Disease proof-of-concept study and plans to host a conference call and webcast at 4:30 p.m. E.D.T. to discuss remission data from the trial. The presentation used for this call is filed as a separate exhibit.
Immunovant, Inc. reported voting results from its 2025 Annual Meeting of Stockholders held on August 27, 2025. A total of 165,885,480 shares of common stock and Series A preferred stock were represented, about 97% of the shares entitled to vote, indicating very high participation.
Stockholders elected Jacob Bauer, Douglas Hughes and Robert Susman to the Board of Directors until the 2026 annual meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending March 31, 2026, with 165,422,634 votes for, 7,237 against and 455,609 abstaining.
In addition, stockholders approved, on a non-binding advisory basis, the compensation of Immunovant’s named executive officers, with 158,995,232 votes for, 1,244,731 against, 4,437 abstaining and 5,641,080 broker non-votes.
Immunovant, Inc. furnished an update on its business by issuing a press release with financial results for its fiscal first quarter ended June 30, 2025. The company reported these results publicly on August 11, 2025, and attached the press release as Exhibit 99.1.
The disclosure is made under the Results of Operations and Financial Condition section and is treated as furnished rather than filed, which limits certain legal liabilities. The report is signed on behalf of Immunovant by Chief Financial Officer Tiago Girao on August 11, 2025.